NeOnc Technologies Holdings, In
NTHI
Positions held
Your positionsNTHI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $72.88M | Enterprise value | $64.38M | Trailing P/E | — | Forward P/E | -2.32 |
| PEG | — | Price / book | -2.90 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -1044.2% |
| Profit margin | 0.0% | ROE | — | ROA | -6.3% | Debt / equity | — |
| Current ratio | 0.18 | Free cash flow | $5.40M | Analyst recommendation | strong_buy | Mean target | $17.00 |
| 52w high | $12.09 | 52w low | $2.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$14.2M | -$8.8M | -$15.5M | -$8.6M | -$5.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$13.6M | -$7.0M | -$13.6M | -$6.9M | -$5.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.1M | $0.1M | $0.0M | — |
| Op margin | -145459.4% | -8605.4% | -11492.2% | -14188.0% | — |
| Net income | -$62.1M | -$11.9M | -$14.9M | -$3.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$58.2M | -$7.1M | -$8.1M | -$2.8M | — |
Headlines — watch
• [WARN · balance sheet] NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilutio
• [WARN · balance sheet] NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilutio
News
2026-09-28 · NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
2026-09-28 · NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
2026-08-17 · NeOnc Technologies Holdings Inc (NTHI) (Q2 2026) Earnings Call Highlights: First Annual Meeting ...
2026-08-13 · Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
2026-08-12 · NeOnc Technologies shares jump after positive Phase 2a glioma results
2026-08-12 · NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
Price (daily)
Full chart · RSI · MACD · patterns